Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.
Banik D, Noonepalle S, Hadley M, Palmer E, Gracia-Hernandez M, Zevallos-Delgado C, Manhas N, Simonyan H, Young CN, Popratiloff A, Chiappinelli KB, Fernandes R, Sotomayor EM, Villagra A. Banik D, et al. Among authors: palmer e. Cancer Res. 2020 Sep 1;80(17):3649-3662. doi: 10.1158/0008-5472.CAN-19-3738. Epub 2020 Jun 30. Cancer Res. 2020. PMID: 32605998 Free PMC article.
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, Kozikowski A, Villagra A. Knox T, et al. Among authors: palmer e. Sci Rep. 2019 Apr 16;9(1):6136. doi: 10.1038/s41598-019-42237-3. Sci Rep. 2019. PMID: 30992475 Free PMC article.
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, Kozikowski A, Villagra A. Knox T, et al. Among authors: palmer e. Sci Rep. 2019 Oct 10;9(1):14824. doi: 10.1038/s41598-019-51403-6. Sci Rep. 2019. PMID: 31597938 Free PMC article.
Author Correction: Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
Moufarrij S, Srivastava A, Gomez S, Hadley M, Palmer E, Austin PT, Chisholm S, Diab N, Roche K, Yu A, Li J, Zhu W, Lopez-Acevedo M, Villagra A, Chiappinelli KB. Moufarrij S, et al. Among authors: palmer e. Sci Rep. 2021 Dec 20;11(1):24423. doi: 10.1038/s41598-021-04066-1. Sci Rep. 2021. PMID: 34931014 Free PMC article. No abstract available.
Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer.
Gomez S, Cox OL, Walker RR 3rd, Rentia U, Hadley M, Arthofer E, Diab N, Grundy EE, Kanholm T, McDonald JI, Kobyra J, Palmer E, Noonepalle S, Villagra A, Leitenberg D, Bollard CM, Saunthararajah Y, Chiappinelli KB. Gomez S, et al. Among authors: palmer e. J Immunother Cancer. 2022 Nov;10(11):e004974. doi: 10.1136/jitc-2022-004974. J Immunother Cancer. 2022. PMID: 36343976 Free PMC article.
1,343 results